Evidence map›Paper›PMID 28763267›Full record

ArticleAnnals of the American Thoracic Society2017

An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.

Arnold S Kristof, Basil J Petrof, Qutayba Hamid, Martin Kolb, Jennifer S Landry, Alex MacKenzie, Francis X McCormack, Inga J Murawski, Joel Moss, Frank Rauch and 8 more

Open access · greenAbstract read
In one paragraph

Article in Annals of the American Thoracic Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Arnold S Kristof
Basil J Petrof
Qutayba Hamid
Martin Kolb
Jennifer S Landry
Alex MacKenzie
Francis X McCormack
Inga J Murawski
Joel Moss
Frank Rauch
Ivan O Rosas
Adam J Shapiro
Benjamin M Smith
David Y Thomas
Bruce C Trapnell
Lisa R Young
Maimoona A Zariwala
ATS Assembly on Respiratory Cell and Molecular Biology

Funding

Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)ZIAHL002541 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI MOSS, JOEL · 2009 to 2025
$47.7M
Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6M
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary DyskinesiaU54HL096458 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIS, STEPHANIE DUGGINS · 2009 to 2023
$20.0M
Mechanisms of Pulmonary Fibrosis in Hermansky-Pudlak SyndromeR01HL119503 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI YOUNG, LISA R. · 2013 to 2021
$3.6M
NHLBI NIH HHS P01 HL092870NHLBI NIH HHS R01 HL119503NHLBI NIH HHS U54 HL096458
6 · The paper itself

Abstract

Rare respiratory diseases (RRDs) are a heterogeneous group of disorders that collectively represent a significant health care burden. In recent years, strong advocacy and policy initiatives have led to advances in the implementation of research and clinical care for rare diseases. The development of specialized centers and research networks has facilitated support for affected individuals as well as emerging programs in basic, translational, and clinical research. In selected RRDs, subsequent gains in knowledge have informed the development of targeted therapies and effective diagnostic tests, but many gaps persist. There was therefore a desire to identify the elements contributing to an effective translational research program in RRDs. To this end, a workshop was convened in October 2015 with a focus on the implementation of effective transnational research networks and collaborations aimed at developing novel diagnostic and therapeutic tools. Key elements included an emphasis on molecular pathogenesis, the continuing engagement of patient advocacy groups and policy makers, the effective use of preclinical models in the translational research pipeline, and the detailed phenotyping of patient cohorts. During the course of the workshop, current logistical and knowledge gaps were identified, and new solutions or opportunities were highlighted.

Indexed as

Translational Research, BiomedicalAnimalsClinical Trials as TopicConsensus Statements as TopicGenetic Association StudiesHumansLung DiseasesMiceRare DiseasesSocieties, MedicalUnited States

Identifiers

PMID28763267
PMCPMC5946685
OpenAlexW2740512042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.